{"nctId":"NCT01797484","briefTitle":"Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia","startDateStruct":{"date":"2013-08"},"conditions":["Coronary Artery Disease","Acute Myocardial Ischemia"],"count":20,"armGroups":[{"label":"Ranolazine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ranolazine"]},{"label":"No additional medication","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Ranolazine","otherNames":["Ranexa"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Proof of acute cardiac ischemia by elevated serum Troponin T-hs levels \\> 14 pg/nl\n* Proof of myocardial dyskinesia with functional echocardiography (\"speckle tracking\")\n* Stable angina pectoris \\>/= CCS II in patient history\n* Stabilized (i.e. normalized vital parameters) patients after coronary angioplasty or angiography\n* Coronary angioplasty or angiography not older than 24 hours\n* Written informed consent\n* Established standard therapy for coronary artery disease (i.e. Beta-Blocker, ACE-Inhibitor or AT1-Inhibitor, ASS, Clopidogrel, Statins)\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age\n* Acute cardio-pulmonary decompensation\n* Middle and high grade liver insufficiency (Child-Pugh Score B and C)\n* High grade renal insufficiency (Creatinine-Clearance \\< 30 ml/min)\n* Concomitant treatment with potent inhibitors of CYP3A4\n* Concomitant administration of class Ia (e.g. quinidine) or class III (e.g. dofetilide, sotalol) antiarrhythmics, except for amiodarone\n* Concomitant administration of \\> 20 mg simvastatin/day\n* Patients with heart failure classification NYHA III and NYHA IV\n* Homeless patients and drug-addicted patients\n* Pregnant and/or breast-feeding women\n* Treatment with Ranolazine prior to enrolment in RIMINI-Trial\n* Allergy against Ranolazine","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Left Ventricular Global Strain Rate","description":"Relativ acceleration or deceleration (1/s) of left ventricular myocardial sections compared to direct opposite section. The more positive the value, the more simultaneously the movements, the more hemodynamically better.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":"2"},{"groupId":"OG001","value":"23","spread":"3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":[]}}}